Display options
Cite
Loaiciga K, Beckmann M, Niederacher D, et al. P(185/Her2) and ps2 protein overexpression in breast-cancer specimens - improvement for prediction of response to endocrine therapy. Oncol Rep. 1994;1(3):625-9doi: 10.3892/or.1.3.625.
Loaiciga, K., Beckmann, M., Niederacher, D., Tutscheck, B., Engels, K., Klockenbusch, W., Schnurch, H., & Bender, H. (1994). P(185/Her2) and ps2 protein overexpression in breast-cancer specimens - improvement for prediction of response to endocrine therapy. Oncology reports, 1(3), 625-9. https://doi.org/10.3892/or.1.3.625
Loaiciga, K, et al. "P(185/Her2) and ps2 protein overexpression in breast-cancer specimens - improvement for prediction of response to endocrine therapy." Oncology reports vol. 1,3 (1994): 625-9. doi: https://doi.org/10.3892/or.1.3.625
Loaiciga K, Beckmann M, Niederacher D, Tutscheck B, Engels K, Klockenbusch W, Schnurch H, Bender H. P(185/Her2) and ps2 protein overexpression in breast-cancer specimens - improvement for prediction of response to endocrine therapy. Oncol Rep. 1994 May;1(3):625-9. doi: 10.3892/or.1.3.625. PMID: 21607415.
Copy Download .nbib Format: NLM
Share it on

Oncol Rep. 1994 May;1(3):625-9. doi: 10.3892/or.1.3.625.

P(185/Her2) and ps2 protein overexpression in breast-cancer specimens - improvement for prediction of response to endocrine therapy.

Oncology reports

K Loaiciga, M Beckmann, D Niederacher, B Tutscheck, K Engels, W Klockenbusch, H Schnurch, H Bender

Affiliations

  1. UNIV DUSSELDORF,FRAUENKLIN,DEPT OBSTET & GYNECOL,D-40225 DUSSELDORF,GERMANY. UNIV DUSSELDORF,BIOL MED FORSCHUNGZENTRUM,DUSSELDORF,GERMANY.

PMID: 21607415 DOI: 10.3892/or.1.3.625

Abstract

Simultaneous analyses of p(185/Her2) and pS2 protein expression in breast cancer is discussed to add information about prognosis and response to endocrine treatment. In a retrospective study, expression of p(185/Her2) and pS2 protein were detected by immunohistochemistry in paraffinembedded, formalin-fixed sections of 219 primary breast cancers. Median age was 56.6 years, median follow-up 168 months. Results were correlated with clinical parameters and steroid receptor status. ER was positive in 55%, PgR in 54% of the tumors. ER correlated inversely with tumor size, and with tumor grade. pS2 was detected in 54% of the tumors, but showed no correlations with other parameters. p(185/Her2) was present in 24% of the tumors and correlated positively with tumor size. pS2 and ER or PgR status correlated (p<0.001). In the sub-group of negative steroid receptors and positive pS2 a qualitative significant difference for p(185/Her2) expression was seen. ER, pS2 and p(185/Her2) status had no prognostic impact on disease-free or overall survival; PgR status correlated with clinical outcome.

Publication Types